DE69631896D1 - Murines modell für menschliche karzinome - Google Patents

Murines modell für menschliche karzinome

Info

Publication number
DE69631896D1
DE69631896D1 DE69631896T DE69631896T DE69631896D1 DE 69631896 D1 DE69631896 D1 DE 69631896D1 DE 69631896 T DE69631896 T DE 69631896T DE 69631896 T DE69631896 T DE 69631896T DE 69631896 D1 DE69631896 D1 DE 69631896D1
Authority
DE
Germany
Prior art keywords
ovarian
murine model
breast
prostate
human carcinomas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69631896T
Other languages
German (de)
English (en)
Inventor
Repasky Subjeck
Harvey Buffalo Bumpers
Heather Secrist
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Application granted granted Critical
Publication of DE69631896D1 publication Critical patent/DE69631896D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Husbandry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69631896T 1995-11-13 1996-11-13 Murines modell für menschliche karzinome Expired - Lifetime DE69631896D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/556,659 US5986170A (en) 1995-11-13 1995-11-13 Murine model for human carcinoma
PCT/US1996/018243 WO1997018300A2 (en) 1995-11-13 1996-11-13 Murine model for human carcinoma

Publications (1)

Publication Number Publication Date
DE69631896D1 true DE69631896D1 (de) 2004-04-22

Family

ID=24222286

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69631896T Expired - Lifetime DE69631896D1 (de) 1995-11-13 1996-11-13 Murines modell für menschliche karzinome

Country Status (7)

Country Link
US (2) US5986170A (enExample)
EP (1) EP0866655B1 (enExample)
JP (1) JP2000500653A (enExample)
AT (1) ATE261654T1 (enExample)
AU (1) AU1158997A (enExample)
DE (1) DE69631896D1 (enExample)
WO (1) WO1997018300A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5986170A (en) * 1995-11-13 1999-11-16 Corixa Corporation Murine model for human carcinoma
US6730512B2 (en) * 1997-04-09 2004-05-04 Amdl, Inc. Combination immunogene therapy
AU2447999A (en) * 1997-09-26 1999-05-03 Corixa Corporation Murine model for human carcinoma
US20040033230A1 (en) * 1997-12-24 2004-02-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US20050260177A1 (en) * 1998-06-05 2005-11-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
US6623923B1 (en) 1998-12-23 2003-09-23 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6387697B1 (en) 1998-12-28 2002-05-14 Corixa Corporation Compositions for treatment and diagnosis of breast cancer and methods for their use
US6586572B2 (en) 1998-12-28 2003-07-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6958361B2 (en) * 1998-12-28 2005-10-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6528054B1 (en) 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6680197B2 (en) 1998-12-28 2004-01-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6969518B2 (en) * 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6590076B1 (en) 1999-04-02 2003-07-08 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6844325B2 (en) 1998-12-28 2005-01-18 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US7598226B2 (en) * 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6573368B2 (en) 1998-12-28 2003-06-03 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6518237B1 (en) 1998-12-28 2003-02-11 Corixa Corporation Compositions for treatment and diagnosis of breast cancer and methods for their use
AU1807401A (en) * 1999-11-30 2001-06-12 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
AU2001255394B2 (en) 2000-04-13 2006-04-13 Superderivatives, Inc. Method and system for pricing options
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
AU2002212568B2 (en) 2001-10-13 2009-07-23 Superderivatives, Inc. Method and system for pricing financial derivatives
CA2528669A1 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CA2554779A1 (en) * 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP2511298B1 (en) 2005-10-31 2019-01-16 Oncomed Pharmaceuticals, Inc. Compositions and Methods for Treating Cancer based on human FZD receptors
US7723112B2 (en) 2005-10-31 2010-05-25 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
TWI506037B (zh) 2008-09-26 2015-11-01 Oncomed Pharm Inc 捲曲結合劑類及彼等之用途
US20110318387A1 (en) * 2009-02-27 2011-12-29 Hiroyuki Satofuka Immunization method using cancer cells
AU2011203381A1 (en) 2010-01-04 2012-08-16 Superderivatives, Inc. Device, method and system of pricing financial instruments
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
WO2011123785A2 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
EP2444484B1 (en) * 2010-08-25 2019-02-06 Order-made Medical Research Inc. Method for producing antibodies using cancer cells
WO2012145535A2 (en) * 2011-04-19 2012-10-26 H. Lee Moffitt Cancer Center & Research Institute, Inc. Animal model of human cancer and methods of use
EP2911691B1 (en) 2012-10-23 2018-10-10 OncoMed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3853201T2 (de) * 1987-12-23 1995-09-14 Univ Leland Stanford Junior Schimäre immunkompromittierende Säugetiere und ihre Verwendung.
US5491284A (en) * 1988-10-05 1996-02-13 Anticancer Incorporated Nude mouse model for neoplastic disease
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
DK0481058T3 (da) * 1990-05-03 1996-12-02 Systemix Inc Humant, lymfatisk væv i en immunokompromitteret vært
JPH04252128A (ja) * 1990-08-03 1992-09-08 Systemix Inc 免疫化された宿主における変性された異種移植器官系
JPH06503001A (ja) * 1991-08-02 1994-04-07 システミックス，インコーポレイティド 免疫不全宿主における原基移植物
US5986170A (en) * 1995-11-13 1999-11-16 Corixa Corporation Murine model for human carcinoma

Also Published As

Publication number Publication date
JP2000500653A (ja) 2000-01-25
WO1997018300A2 (en) 1997-05-22
ATE261654T1 (de) 2004-04-15
US6284239B1 (en) 2001-09-04
EP0866655A2 (en) 1998-09-30
EP0866655B1 (en) 2004-03-17
US5986170A (en) 1999-11-16
WO1997018300A3 (en) 1997-07-24
AU1158997A (en) 1997-06-05

Similar Documents

Publication Publication Date Title
ATE261654T1 (de) Murines modell für menschliche karzinome
DE3687736D1 (de) Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung.
DE69738077D1 (de) Tiermodelle für die menschliche prostatakrebsfortschreitung
ES2058083T3 (es) Anticuerpos monoclonales contra el factor humano de la necrosis tumoral (tnf) y su empleo.
ATE307601T1 (de) Brustkrebsbehandlung mittels natürlicher ätherischer öle
ES8705975A1 (es) Un metodo de deteccion o localizacion de celulas de carcinoma humano.
IL87885A0 (en) Compounds having antiprogestational and anti-estrogenic activities for the treatment of tumours
KR970704410A (ko) 암 치료용 종양 세포를 함유하는 이식 장치(Implanted Device Containing Tumor Cells for the Treatment of Cancer)
IL214084A (en) Kit containing antibodies against antibb2 and instructions for use in breast cancer treatment
FR2409053A1 (fr) Applicateur pour thermotherapie hyperthermique
EP0161941A3 (en) Monoclonal antibody useful in the diagnosis of human stomach or breast cancer
ATE140480T1 (de) Menschliches lymph-gewebe in einem wirt mit angegriffenem immunsystem
NZ210867A (en) Tumour-specific monoclonal antibodies, production thereof and use
TR199800443T1 (xx) Hidroliz y�kseltici taksan hidrofobik t�revleri.
DE69411733D1 (de) Nachweis von prostat-spezifischen antigen in brusttumoren
NZ512877A (en) Using hair to screen for breast cancer
NO20002412D0 (no) FremgangsmÕte for behandling av tumorer og tumorceller ved anvendelse av ex vivo aktiverte T celler
ATE239781T1 (de) Immortalisierte menschliche prostata- epithelzellen und klone und ihre verwendungen zur untersuchung und therapie von prostata-krebs
Plettenberg et al. Merkel cells and Merkel cell carcinoma express the BCL‐2 proto‐oncogene
ES8704082A1 (es) Procedimiento para preparar un agente terapeutico a base de celulas tumorales humanas y eventualmente, neuraminidasa.
EP0189849A3 (en) Method for treatment of neuroectodermal malignancies and epithelial carcinomas in humans
PT821060E (pt) Mutacoes de e-caderina como base para o diagnostico e a terapia de tumores humanos malignos
CA2237300A1 (en) Murine model for human carcinoma
DE69619683D1 (de) Expression von heterologen genen in menschlichen brustzellen, einschliesslich menschliche brustkarzionomzellen unter der kontrolle von regulatorischen sequenzen von wap oder mmtv
EP0162825A3 (en) The use of a specific carcinom associated antigen (hapten), fucosylsialosylgangliotetraose (fuc-gm1) in diagnostic or therapeutic procedures related to human lung cancer (small cell carcinomas)

Legal Events

Date Code Title Description
8332 No legal effect for de